ENVERIC BIOSCIENCES, INC.
Income Statement
| Line Item | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.5M | $8.3M | $9.6M | $9.1M | $9.1M | $11.0M | $10.7M | $10.3M |
| Cost of Revenue | $6.6M | $6.4M | $7.7M | $7.3M | $7.2M | $8.6M | $8.5M | $8.4M |
| Gross Profit | $1.9M | $1.8M | $1.9M | $1.7M | $1.9M | $2.4M | $2.1M | $1.9M |
| Gross Margin | 22.3% | 22.0% | 19.6% | 19.1% | 20.8% | 21.6% | 20.0% | 18.5% |
| Operating Expenses | ||||||||
| Research & Development | $63.3K | $51.0K | — | — | — | — | — | — |
| SG&A Expense | $426.5K | $716.6K | $836.7K | $-6.8M | $2.9M | $3.3M | $2.9M | $2.7M |
| Operating Income | $-489.8K | $-767.5K | $-836.7K | $2.0M | $-1.6M | $-1.5M | $-1.3M | $-10.8M |
| Operating Margin | -5.8% | -9.3% | -8.7% | 22.5% | -17.1% | -13.4% | -12.1% | -105.0% |
| Interest Expense | $75.5K | $50.9K | $261.8K | $-470.0K | $252.6K | $156.7K | $142.6K | $145.8K |
| Pretax Income | $-989.0K | $-1.6M | $-1.8M | $-2.1M | $40.2K | $-1.2M | $-1.9M | $-13.4M |
| Income Tax Expense | $-27.9K | $17.5K | $21.9K | $404.3K | $-1.1K | $16.6K | $-31.2K | $6.3M |
| Net Income | $-565.3K | $-818.4K | $-1.1M | $664.6K | $41.3K | $-1.3M | $-1.9M | $-19.8M |
| Net Margin | -6.7% | -9.9% | -11.4% | 7.3% | 0.5% | -11.4% | -17.4% | -192.2% |
| EPS (Basic) | $0.00 | $-0.01 | $-0.01 | $-0.01 | $0.00 | $0.00 | $-0.01 | $-0.14 |
| EPS (Diluted) | $0.00 | $-0.01 | $-0.01 | $-0.01 | $0.00 | $0.00 | $-0.01 | $-0.14 |
| Shares Outstanding (Basic) | 380.8M | 253.3M | 407.1M | 380.7M | 304.3M | 291.9M | 260.3M | 137.0M |
| Shares Outstanding (Diluted) | 380.8M | 253.3M | 228.6M | 153.3M | 304.3M | 291.9M | 260.3M | 137.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |